UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 11, 2007
Emergent BioSolutions Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
001-33137 |
14-1902018 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission |
(IRS Employer |
|
2273 Research Boulevard, Suite 400, Rockville, Maryland |
20850 |
|
(Address of Principal Executive Offices) |
(Zip Code) |
(301) 795-1800
Registrant’s telephone number, including area code:
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On May 16, 2007, the Board of Directors of Emergent BioSolutions Inc. (the “Company”) appointed Daniel J. Abdun-Nabi, the Company’s president and secretary, to the additional position of chief operating officer. Mr. Abdun-Nabi, age 52, has served as president since April 2007 and as secretary since December 2004. Mr. Abdun-Nabi served as senior vice president corporate affairs and general counsel of the Company from December 2004 to April 2007 and as vice president and general counsel of the Company from May 2004 to December 2004. Mr. Abdun-Nabi served as general counsel for IGEN International, Inc., a biotechnology company, and its successor BioVeris Corporation, from September 1999 to May 2004. Prior to joining IGEN, Mr. Abdun-Nabi served as senior vice president, legal affairs, general counsel and secretary of North American Vaccine, Inc. Mr. Abdun-Nabi received an L.L.M. in taxation from Georgetown University Law Center, a J.D. from the University of San Diego School of Law and a B.A. in political science from the University of Massachusetts, Amherst. There are no family relationships between Mr. Abdun-Nabi and any executive officer or director of the Company.
On May 11, 2007, Edward J. Arcuri, Ph.D. notified the Company of his decision to resign as chief operating officer. Mr. Arcuri’s resignation will be effective as of May 16, 2007.
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: May 16, 2007 |
EMERGENT BIOSOLUTIONS INC. | |
|
|
By: |
/s/R. Don Elsey |